Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bacil PharmaBOM:524516 -4.99%33 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates BOM:524516 with a GF Score™ of 33/100. Among 960 Drug Manufacturers companies, Bacil Pharma ranks worse than 104166.56% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bacil Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹-0.75 Mil. Bacil Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹0.00 Mil. Therefore, Bacil Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bacil Pharma EBITDA Margin % Related Terms
Bacil Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bacil Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bacil Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bacil Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bacil Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bacil Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bacil Pharma (BOM:524516) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bacil Pharma and its competitors. According to the industry distribution chart, Bacil Pharma ranks #999999 out of 960 companies in the Drug Manufacturers industry.
Is Bacil Pharma's EBITDA Margin % too high?
Bacil Pharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Bacil Pharma ranks #999999 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bacil Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Bacil Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bacil Pharma ranks #999999 out of 960 companies for EBITDA Margin %. This places Bacil Pharma in the lower half of its industry. The industry median EBITDA Margin % is 12.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bacil Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bacil Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bacil Pharma stock overvalued right now?
Bacil Pharma (BOM:524516) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Bacil Pharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bacil Pharma (BOM:524516), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bacil Pharma Ltd is an Indian-based pharmaceutical company engaged in healthcare solutions, basically in the development, manufacturing, and distribution of a range of pharmaceutical products across therapeutic segments. operating in a single segment. The product of the company includes tablets, capsules, injectables, ointments, and specialty products.
33GF Score
Get the complete analysis for BOM:524516
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524516 has been successfully added to your 
